Document is current
Any future updates will be listed below
-
Authors
Leeyaphan, Charussri
Punnakitikashem, Primana
Suiwongsa, Bordeesuda
Komesmuneeborirak, Phojana
Chongtrakool, Piriyaporn
Kulthanachairojana, Nattanichcha
Limphoka, Pichaya
Hutachoke, Thrit
Saengthong-aram, Phuwakorn
Kobkurkul, Pantaree
Wongdama, Supisara
Pongkittilar, Bawonpak
Matthapan, Lalita
Panyawong, Chatisa
Prasong, Waranyoo
Plengpanich, Akkarapong
Kunwong, Natsuda
Rodponthukwaji, Kamonlatth
Bunyaratavej, Sumanas https://orcid.org/0000-0002-0852-7742
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05901961 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy, Safety, and Cost-effectiveness of Zinc Oxide Nanoparticles in Whitfield’s Spirit Solution for Treating Superficial Fungal Foot Infections: A Randomized Controlled Trial
https://doi.org/10.1007/s13555-025-01340-2
-
Funding
Funding for this research was provided by:
Dermatological Society of Thailand
Thailand Center of Excellence for Life Sciences
Center of Excellence on Medical Biotechnology
S&T Postgraduate Education and Research Development Office
Commission on Higher Education, Thailand
- License Information
-
More Information
Article History
Received: 11 October 2024
Accepted: 14 January 2025
First Online: 27 January 2025
Declarations
:
: The authors, Charussri Leeyaphan, Primana Punnakitikashem, Bordeesuda Suiwongsa, Phojana Komesmuneeborirak, Piriyaporn Chongtrakool, Nattanichcha Kulthanachairojana, Pichaya Limphoka, Thrit Hutachoke, Phuwakorn Saengthong-aram, Pantaree Kobkurkul, Supisara Wongdama, Bawonpak Pongkittilar, Lalita Matthapan, Chatisa Panyawong, Waranyoo Prasong, Akkarapong Plengpanich, Natsuda Kunwong, Kamonlatth Rodponthukwaji, Sumanas Bunyaratavej, declare that they have no competing interests.
: This randomized, double-blinded, controlled trial was conducted at the Department of Dermatology, Faculty of Medicine, Siriraj Hospital, Mahidol University in Bangkok, Thailand, from June 2023 to September 2023. The Siriraj Institutional Review Board approved the study (COA no. Si742/2020), and it was registered with ClinicalTrials.gov (NCT05901961) June 5, 2023. The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. All participants provided informed consent to participate in the study and consent for publication if any identifying information is included in the manuscript.
